Guidelines International Network (GIN)
Powered by EBSCO

Guidelines International Network

2001 - 2010 of 3572 results found

Management of HIV Infection in Pregnant Women

MeSH Terms
Pregnancy (G08.520.769); Sexually Transmitted Diseases; Viral (C02.800.801); RNA Virus Infections (C02.782); HIV Infections (C20.673.480); HIV Infections (C02.800.801.400); HIV Infections (C02.782.815.616.400); Female Genital Diseases and Pregnancy Complications (C13); Immune System Disorders / Immunologic Diseases (C20); Reproduction (G08.520); Sexually Transmitted Diseases (C01.539.780 / C02.800); Virus Infections (C02); Pregnancy Complications (C13.703); Immunologic Deficiency Syndromes (C20.673)
Publication Scope
management
Countries of Application
Malaysia
Guideline Publication Status
Published
Languages
English
Authors
HTA DoH (MY)
Publication Year
2008

Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline

MeSH Terms
Blood Glucose
Blood Glucose Self-Monitoring
Diabetes Mellitus* / drug therapy
Humans
Hyperglycemia* / drug therapy
Hypoglycemic Agents
Insulin
Systematic Reviews as Topic
Guideline Contact
Maureen Corrigan, [email protected]
Keywords
Blood Glucose Blood Glucose Self-Monitoring Diabetes Mellitus* / drug therapy Humans Hyperglycemia* / drug therapy Hypoglycemic Agents Insulin Systematic Reviews as Topic
Date of Last Evidence Search
Dec-21
Methods Applied
This guideline was developed using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology (128). A detailed description of the Endocrine Society guideline development program can be found online at https://www.endocrine.org/clinical-practice-guidelines/methodology. This methodology includes the use of EtD frameworks to ensure all important criteria are considered when making recommendations (129, 130). The process was facilitated by the GRADEpro Guideline Development Tool (GRADEpro GDT) (131). The GDP consisted of 11 content experts representing the following specialties: endocrinology, internal medicine, primary care, nursing, pharmacy, and diabetes education. A patient representative was also included on the panel. Members were identified by the Endocrine Society Board of Directors and the Clinical Guidelines Committee (CGC) and were vetted according to the conflict-of-interest policy (132), which was adhered to throughout the guideline process to manage and mitigate conflicts of interest. Detailed disclosures of panel members and the management strategies implemented during the development process can be found in Appendix A. In addition, the group included a clinical practice guideline methodologist from the Mayo Evidence-Based Practice Center, who led the team that conducted the systematic reviews and meta-analyses, and a methodologist from the McMaster University GRADE Centre, who advised on methodology and moderated the application of the EtD framework and development of the recommendations. Two GDP members were assigned to lead each guideline question. The questions addressed in this guideline were prioritized from an extensive list of potential questions through a survey and discussion; 10 questions were identified as most important. The Mayo Evidence-Based Practice Center conducted a systematic review for each question and produced GRADE evidence profiles that summarized the body of evidence for each question and the certainty of the evidence (11). The systematic searches for evidence were conducted on July 2020 and updated in December 2021. In parallel to the development of the evidence summaries, the GDP members searched for and summarized research evidence for other EtD criteria, such as patients’ values and preferences, feasibility, acceptability, costs/resource use, cost-effectiveness, and health equity. Research evidence summaries noted in the EtD frameworks were compiled using standardized terminology templates for clarity and consistency (133). During a series of video conferences, the GDP judged the balance of benefits and harms, in addition to the other EtD criteria, to determine the direction and strength of the recommendation (Table 4 and 5) (133-136).
Publication Scope
assessment
Clinical Assessment
management
Patient education
treatment
Guideline Publication Status
Living guideline
Languages
English
Authors
Endocrine Society
Willingness to Collaborate
Yes
Publication Year
2022
Name of Endorsing Organization
European Society of Endocrinology

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

MeSH Terms
Immunotherapy (E02.095.465.425); Neoplasms (C04)
Guideline Contact
[email protected]
Publication Date
14-Feb-18
Publication Scope
management
Countries of Application
United States
Guideline Publication Status
Under Review
Languages
English
Authors
ASCO (US)
Publication Year
2018

Management of ImmuneThrombocytopenic Purpura

MeSH Terms
Blood Coagulation Disorders (C15.378.100); Hematological Disorders / Hemic and Lymphatic Diseases (C15); Immune System Disorders / Immunologic Diseases (C20); Hematologic Diseases (C15.378)
Publication Scope
management
Countries of Application
Malaysia
Guideline Publication Status
Published
Languages
English
Authors
HTA DoH (MY)
Publication Year
2006

Management of lung cancer (SIGN CPG 137)

MeSH Terms

Diagnostic Imaging (E01.370.350); Thoracic Surgical Procedures (E04.928); Radiotherapy (E02.815); Palliative Care (N02.421.585.666); Lung Neoplasms (C04.588.894.797.520); Respiratory Tract Diseases (C08)

Guideline Contact
Ailsa Stein ([email protected])
Date for Review
2001-02-17
Publication Scope
management
Countries of Application
United Kingdom
Guideline Publication Status
Published
Languages
English
Authors
SIGN (GB)
Publication Year
2014